Peter Kolchinsky portfolio

RA Capital Management · Biotechnology specialist

RA Capital Management's 13F filing for Q2 2026, filed with the SEC on August 14, 2026, reports $11.5B across 84 US-listed positions. The largest holding is ASND at 23.8% of the portfolio; the ten largest make up 60%. The largest buy last quarter was PBLS, a new position ($791.9M).

Reported value
$11.5B
Positions
84
In the top 10
60%
Quarter
Q2 2026
filed Aug 14

Key facts

13F portfolio value
$11.5BQ2 2026
Positions
84
Largest holding
ASND 23.8%
Top 10 share
60%
New positions
16since Q1 2026
Sold out
17
Filed
Aug 14, 2026
Next 13F due
Nov 16, 2026Q3 2026

Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Source: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824).

Prices as of .

Compared with Q1 2026, Peter Kolchinsky opened 16 new positions (PBLS, COAG, ABVX…), added to 10, trimmed 10, sold out of 17 (DNTH, PRAX, SRPT…).

By sector, Health Care is the largest at 43% of the reported portfolio, followed by Technology at 0%; 57% is in securities with no sector on file.

26 of the 84 positions listed have been in every one of the last 9 quarterly filings.

Peter Kolchinsky top holdings: stocks in the Q2 2026 13F

Peter Kolchinsky holdings, Q2 2026
#StockSectorShare of portfolioValueSharesReported pricePrice nowSince period endHeldLast quarter
1Ascendis Pharma A/SASNDHealth Care23.8%$2.7B10.28M$266.72$267.09 0.1% up9+ qtrs—
2Parabilis Medicines IncPBLS—6.88%$791.9M28.93M$27.37$28.17 2.9% up1 qtrNew
3Rhythm Pharmaceuticals IncRYTMHealth Care6.43%$740.2M6.67M$111.03$113.28 2.0% up9+ qtrsNo change
4Vaxcyte IncPCVXHealth Care5.80%$667M11.47M$58.13$59.98 3.2% up9+ qtrsNo change
5Sionna Therapeutics IncSION—3.79%$435.7M9.91M$43.99$3.07 93.0% down6 qtrsNo change
6Tyra Biosciences IncTYRA—3.39%$389.6M12.2M$31.94$19.88 37.8% down9+ qtrsNo change
7Edgewise Therapeutics IncEWTXHealth Care2.96%$341M8.39M$40.63$42.07 3.5% up9+ qtrs▼ Reduced 20%
8Newamsterdam Pharma CompanyNAMS—2.81%$323.7M9.55M$33.89$19.39 42.8% down9+ qtrsNo change
9Hemab Therapeutics HoldingsCOAG—2.49%$286.8M7.81M$36.73$38.50 4.8% up1 qtrNew
10Septerna IncSEPN—2.04%$234.3M7M$33.49$39.44 17.8% up7 qtrsNo change
11Bicara Therapeutics IncBCAX—1.87%$215.4M7.26M$29.69$9.62 67.6% down8 qtrsNo change
12Mineralys Therapeutics IncMLYS—1.80%$207.6M7.69M$26.98$14.53 46.1% down9+ qtrsNo change
13GH Research PLCGHRS—1.78%$205.3M7.64M$26.88$17.76 33.9% down9+ qtrs▼ Reduced 0.5%
14Disc Medicine IncIRON—1.56%$179.2M2.45M$73.14$76.62 4.8% up6 qtrsNo change
15Spyglass Pharma IncSGP—1.55%$178.6M8.02M$22.26$31.03 39.4% up2 qtrsNo change
16Artiva Biotherapeutics IncARTV—1.51%$174.2M17.96M$9.70$3.90 59.8% down8 qtrs▲ Added 82%
17Janux Therapeutics IncJANX—1.49%$171.9M11.19M$15.36$10.77 29.9% down9+ qtrsNo change
18Taysha Gene Therapies IncTSHA—1.39%$160.4M23.56M$6.81$4.03 40.8% down9+ qtrsNo change
19BioCryst Pharmaceuticals IncBCRX—1.38%$158.3M15.83M$10.00$7.46 25.4% down3 qtrsNo change
20Wave Life Sciences LtdWVE—1.36%$156.7M26.98M$5.81$2.91 49.9% down9+ qtrsNo change
21
Nuvalent Incno ticker on file
—1.34%$153.9M1.25M$123.50——4 qtrs▼ Reduced 51%
22Abivax SAABVX · ADRHealth Care1.31%$150.9M1.13M$133.26$83.02 37.7% down1 qtrNew
23Oruka Therapeutics IncORKAHealth Care1.29%$148M1.55M$95.17$96.48 1.4% up1 qtrNew
24Climb Bio IncCLYM—1.28%$147.4M11.3M$13.04$9.64 26.1% down9+ qtrsNo change
25Solid Biosciences IncSLDB—1.05%$120.2M12.04M$9.99$6.36 36.3% down9+ qtrs▲ Added 29%
26Zai Lab LtdZLAB · ADR—0.95%$109.1M5.74M$19.00$23.46 23.5% up2 qtrs▲ Added 0.6%
27Ars Pharmaceuticals IncSPRY—0.76%$87M10.86M$8.01$3.73 53.5% down9+ qtrsNo change
28Xencor IncXNCR—0.74%$84.9M5.27M$16.10$34.71 115.6% up2 qtrs▲ Added 7.7%
29Jade Biosciences IncJBIO—0.71%$81.6M3.67M$22.22$15.07 32.2% down5 qtrsNo change
30Intellia Therapeutics IncNTLA—0.67%$76.6M4.53M$16.92$9.86 41.8% down1 qtrNew
31LB Pharmaceuticals IncLBRX—0.62%$71.7M2.21M$32.46$40.26 24.0% up4 qtrsNo change
32Definium Therapeutics IncDFTXHealth Care0.61%$70.6M1.5M$47.04$29.27 37.8% down1 qtrNew
33Aclaris Therapeutics IncACRS—0.59%$67.3M12.72M$5.29$3.52 33.6% down2 qtrs▲ Added 87%
344D Molecular TherapeuticsFDMT—0.58%$67.2M5.05M$13.30$10.77 19.0% down9+ qtrsNo change
35Sana Biotechnology IncSANA—0.57%$65.4M18.75M$3.49$1.89 46.0% down1 qtrNew
36Damora Therapeutics IncDMRA—0.54%$62.4M2.4M$26.01$22.36 14.1% down2 qtrs▲ Added 0.02%
37Monopar Therapeutics IncMNPR—0.54%$61.8M667.21K$92.59$70.85 23.5% down7 qtrsNo change
38Acumen Pharmaceuticals IncABOS—0.49%$56.1M20.99M$2.67$0.2110 92.1% down9+ qtrsNo change
39Geron CorpGERN—0.48%$54.8M42.81M$1.28$0.9777 23.6% down9+ qtrs▼ Reduced 33%
40Rezolute IncRZLT—0.43%$49.1M9.45M$5.20$3.79 27.1% down3 qtrs▲ Added 2.9%
41Evommune IncEVMN—0.40%$46.4M3.49M$13.29$7.00 47.4% down3 qtrsNo change
42Vor Biopharma IncVOR—0.38%$44.2M2.4M$18.41$18.49 0.4% up9+ qtrs▼ Reduced 56%
43Century Therapeutics IncIPSC—0.38%$43.5M17.75M$2.45$1.49 39.2% down2 qtrsNo change
44Aktis Oncology IncAKTS—0.37%$42.4M1.31M$32.23$16.20 49.7% down2 qtrs▼ Reduced 13%
45Bioage Labs IncBIOA—0.36%$41M1.67M$24.51$5.18 78.9% down2 qtrs▲ Added 1.3%
46C4 Therapeutics IncCCCC—0.33%$37.4M8M$4.67$2.53 45.8% down3 qtrsNo change
47Mirum Pharmaceuticals IncMIRMHealth Care0.32%$37.3M318.55K$117.07$90.59 22.6% down2 qtrsNo change
48Capricor Therapeutics IncCAPR—0.32%$36.3M1.51M$24.08$8.82 63.4% down3 qtrsNo change
49Pepgen IncPEPG—0.31%$36.1M20.06M$1.80$3.72 106.4% up9+ qtrsNo change
50Prelude Therapeutics IncPRLD—0.30%$34.5M6.48M$5.33$3.33 37.5% down1 qtrNew
51Nkarta IncNKTX—0.27%$30.6M10.81M$2.83$1.26 55.5% down9+ qtrsNo change
52Q32 Bio IncQTTB—0.26%$29.7M2.33M$12.74$8.58 32.7% down1 qtrNew
53Anteris Technologies GlobalAVR—0.26%$29.6M3M$9.85$5.58 43.4% down2 qtrsNo change
54Editas Medicine IncEDIT—0.25%$28.8M8.89M$3.24$1.89 41.8% down1 qtrNew
55Ovid Therapeutics IncOVID—0.25%$28.2M10.5M$2.69$2.28 15.4% down3 qtrs▼ Reduced 2.0%
56Assembly Biosciences IncASMB—0.24%$28M1.02M$27.48$22.33 18.7% down4 qtrsNo change
57Alx Oncology Holdings IncALXO—0.23%$26.9M13.01M$2.07$1.03 50.5% down2 qtrsNo change
58Benitec Biopharma IncBNTC—0.22%$24.8M1.85M$13.38$8.16 39.0% down3 qtrsNo change
59Lenz Therapeutics IncLENZ—0.21%$23.7M4.18M$5.68$3.65 35.8% down9+ qtrsNo change
60Lexeo Therapeutics IncLXEO—0.20%$23.3M5M$4.66$3.09 33.6% down3 qtrsNo change
61Acrivon Therapeutics IncACRV—0.19%$21.8M12.23M$1.78$1.48 16.9% down9+ qtrs▲ Added 47%
62Altimmune IncALT—0.17%$19.8M6.5M$3.04$1.55 49.2% down1 qtrNew
63Karyopharm Therapeutics IncKPTI—0.16%$18.7M1.92M$9.77$0.0174 99.8% down2 qtrsNo change
64Bright Minds Biosciences IncDRUG—0.16%$18.6M265K$70.20$20.86 70.3% down2 qtrsNo change
65Avalo Therapeutics IncAVTX—0.16%$18.5M1M$18.48$7.03 62.0% down8 qtrs▲ Added 51%
66Onkure Therapeutics Inc-AOKUR—0.16%$18.2M4M$4.56$2.56 44.0% down2 qtrsNo change
67Faeth Therapeutics IncFTH—0.16%$18.1M722.02K$25.00$8.73 65.1% down1 qtrNew
68Aura Biosciences IncAURA—0.15%$17.8M2.5M$7.10$7.14 0.6% up1 qtrNew
69Sab Biotherapeutics IncSABS—0.15%$17.2M4.4M$3.90$2.95 24.4% down4 qtrsNo change
70Seaport Therapeutics IncSPTX—0.13%$15.2M700K$21.72$18.27 15.9% down1 qtrNew
71Palisade Bio IncPALI—0.13%$14.9M7.12M$2.09$1.00 52.2% down3 qtrsNo change
72Helix Acquisition CorpHLXC—0.12%$13.3M1.25M$10.64$10.28 3.4% down2 qtrsNo change
73Waystar Holding CorpWAYTechnology0.09%$10.9M529.4K$20.53$28.12 37.0% up3 qtrsNo change
74Equillium IncEQ—0.09%$9.9M3.1M$3.20$1.19 62.8% down2 qtrsNo change
75Macrogenics IncMGNX—0.08%$8.6M1.86M$4.62$2.10 54.7% down2 qtrsNo change
76
Perceptive Cap Solutionsno ticker on file
—0.07%$8.2M750K$10.88——9+ qtrsNo change
77Adicet Bio IncACET—0.07%$8.1M932.62K$8.64$2.77 68.0% down9+ qtrs▼ Reduced 21%
78
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.06%$7.1M333.33K$21.37——9+ qtrsNo change
79Corvus Pharmaceuticals IncCRVS—0.06%$6.7M450K$14.94$10.40 30.4% down2 qtrsNo change
80Rani Therapeutics Holdings-ARANI—0.06%$6.5M8.5M$0.7604$0.5620 26.1% down3 qtrsNo change
81Jatt II Acquisition CorpJATT—0.05%$5.7M500K$11.36$10.20 10.2% down1 qtrNew
82Amanat Acquisition CorpAMAN—0.03%$3.8M375K$10.16$10.10 0.6% down1 qtrNew
83Werewolf Therapeutics IncHOWL—0.01%$859.3K2.39M$0.3599$0.9811 172.6% up9+ qtrs▼ Reduced 64%
84Palatin Technologies IncPTN—0.01%$670.3K62.12K$10.79$5.26 51.3% down3 qtrs▼ Reduced 11%

Peter Kolchinsky latest buys (Q2 2026)

Peter Kolchinsky latest sells (Q2 2026)

  • DNTH Sold$219.2M
  • Nuvalent Inc ▼ Reduced 51%$159M
  • PRAX Sold$120.4M
  • SRPT Sold$84.9M
  • EWTX ▼ Reduced 20%$82.7M
  • SYRE Sold$81.8M
  • VOR ▼ Reduced 56%$55.3M
  • FULC Sold$46.4M
  • OLMA Sold$38.8M
  • DSGN Sold$31.6M

Every buy and sell in Peter Kolchinsky's Q2 2026 13F →

By sector

Peter Kolchinsky portfolio by sector, Q2 2026
SectorShare of portfolioValuePositions
Health Care42.6%$4.9B8
Technology0.09%$10.9M1
No sector on file57.3%$6.6B75

8 quarterly filings on file for RA Capital Management, back to Q3 2024: reported value, position counts, and every buy and sell quarter by quarter.

Filing history →All Q2 2026 13F filings →

Questions about Peter Kolchinsky's portfolio

What stocks does Peter Kolchinsky own?

According to RA Capital Management's 13F filing for Q2 2026, the largest of its 84 US-listed positions are ASND (23.8%), PBLS (6.9%), RYTM (6.4%), PCVX (5.8%) and SION (3.8%). A 13F shows long positions only, as of the quarter's end.

What is Peter Kolchinsky's largest holding?

ASND (Ascendis Pharma A/S), worth $2.7B at the end of Q2 2026, or 23.8% of the $11.5B RA Capital Management reported.

What did Peter Kolchinsky buy last quarter?

In Q2 2026, compared with the filing for Q1 2026, the largest purchases were PBLS (new position, $791.9M), COAG (new position, $286.8M), ABVX (new position, $150.9M), ORKA (new position, $148M) and ARTV (added, $78.6M).

What did Peter Kolchinsky sell last quarter?

In Q2 2026 the largest sales were DNTH (sold out, $219.2M), Nuvalent Inc (reduced, $159M), PRAX (sold out, $120.4M), SRPT (sold out, $84.9M) and EWTX (reduced, $82.7M), against the filing for Q1 2026.

How much is Peter Kolchinsky's portfolio worth?

RA Capital Management reported $11.5B in 84 US-listed positions for Q2 2026, valued at the quarter's end and filed on August 14, 2026. That is the 13F portfolio only: no cash, short positions or most shares listed outside the US.

When does Peter Kolchinsky file the next 13F?

The 13F for Q3 2026, the quarter ending September 30, 2026, was due by November 16, 2026: 45 days after the quarter ends, or the next business day. The latest filing on file here is for Q2 2026, filed on August 14, 2026.

Which sectors does Peter Kolchinsky own?

Health Care 42.6%, Technology 0.1% of the reported portfolio, with 57.3% in securities that have no sector on file here (funds, smaller companies, positions without a ticker).

How long has Peter Kolchinsky held these stocks?

Counting consecutive quarterly filings up to Q2 2026: ASND 9+, PBLS 1, RYTM 9+, PCVX 9+, SION 6, TYRA 9+. “9+” means the position is in every filing looked at, so it may go back further.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio: RA Capital Management 13F holdings (Q2 2026)”, data as of 14 August 2026. https://funkfolio.com/gurus/peter-kolchinsky

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending June 30, 2026.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2026, filed Aug 14, 2026. “Last quarter” compares share counts with the filing for Mar 31, 2026. “Reported price” is the position's reported value divided by its shares — the price the filing implies for the period end. “Price now” is from Yahoo Finance and can be delayed 15 minutes or more; “since period end” sets the two side by side and is left blank where the reported price falls outside the stock's 52-week range, which points to a share split since. A split small enough to stay inside that range is not caught, and dividends are not counted. Sectors are those of the ranked companies on this site; funds, smaller companies and positions without a ticker have none. “Held” counts consecutive quarterly filings the position appears in, out of the 9 looked at. A buy or sell is sized as the shares moved at the price the filing implies; a position sold out at its value in the previous filing. Filings can be 45 days old when published; this is not a live portfolio and not advice.